Factors Informing Individualized Treatment Decision-Making for HER2-Positive Metastatic Breast Cancer

Sara M. Tolaney, MD, MPH explains that treatment decisions for metastatic breast cancer are based on the current biopsy showing receptor status, but prior biopsies over the full course of disease are considered as well, particularly for HER2 targeted therapies which may work even if HER2 low expression occurred years earlier.

Related Content:

Navigating HER2+ Metastatic Breast Cancer TreatmentBreast Cancer

Breast Cancer Survivor Advocates for Access to Scalp Cooling

Scalp Cooling Can Prevent Hair Loss During Chemo for Breast Cancer

Dealing With Peripheral Neuropathy After Breast Cancer Treatment